A 440-patient phase 3 trial found Innovent's dulaglutide biosimilar LY05008 statistically equivalent to Trulicity for blood-sugar control in type 2 diabetes: HbA1c fell 1.44% versus 1.41% at 24 weeks, with similar safety and only about a quarter the hypoglycemia rate. With Trulicity's patent cliff behind it, results like this are how a $6-billion-a-year GLP-1 gets its cheaper copies.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.